PGC1α inhibits polyamine synthesis to suppress prostate cancer aggressiveness

Lisa Kaminski, Stephanie Torrino, Maeva Dufies, Zied Djabari, Romain Haider, Francois Rene Roustan, Emilie Jaune, Kathiane Laurent, Nicolas Nottet, Jean Francois Michiels, Maeva Gesson, Stephane Rocchi, Nathalie M. Mazure, Matthieu Durand, Jean Francois Tanti, Damien Ambrosetti, Stephan Clavel, Issam Ben-Sahra, Frederic Bost*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Abstract

Although tumorigenesis is dependent on the reprogramming of cellular metabolism, the metabolic pathways engaged in the formation of metastases remain largely unknown. The transcriptional coactivator peroxisome proliferator- activated receptor gamma coactivator 1-alpha (PGC1α) plays a pleiotropic role in the control of cancer cell metabolism and has been associated with a good prognosis in prostate cancer. Here, we show that PGC1α represses the metastatic properties of prostate cancer cells via modulation of the polyamine biosynthesis pathway. Mechanistically, PGC1α inhibits the expression of c-MYC and ornithine decarboxylase 1 (ODC1), the rate-limiting enzyme for polyamine synthesis. Analysis of in vivo metastases and clinical data from patients with prostate cancer support the proposition that the PGC1α/c-MYC/ODC1 axis regulates polyamine biosynthesis and prostate cancer aggressiveness. In conclusion, downregulation of PGC1α renders prostate cancer cells dependent on polyamine to promote metastasis.

Original languageEnglish (US)
Pages (from-to)3268-3280
Number of pages13
JournalCancer Research
Volume79
Issue number13
DOIs
StatePublished - 2019

Funding

This work has been supported by the French government, through the UCAJEDI Investments in the Future project managed by the National Research Agency (ANR) with the reference number ANR-15-IDEX- 01. L. Kaminski is supported by the French Ministry of Research. S. Torrino has a grant from the Fondation de France. R. Haider and E. Jaune were supported by the foundation ARC and F.-R. Roustan by the CHU of Nice. I. Ben-Sahra is supported by the NIH R00-CA194192 and LAM Foundation grants. F. Bost, N. M. Mazure, and J.F. Tanti are CNRS investigators. Metabolomics services were performed by theMetabolomics Core Facility at Robert H. LurieComprehensive Cancer Center of Northwestern University and the Beth Israel Deaconess Medical Center Mass Spectrometry Facility of Harvard Medical School. We thank Charlotte Hinault for carefully reading the manuscript. This work was supported by a grant from the Fondation ARC pour la recherche sur le Cancer, l'Association pour la Recherche sur les Tumeurs de la Prostate (ARTP), ITMO-Cancer. This work has been supported by the French government, through the UCAJEDI Investments in the Future project managed by the National Research Agency (ANR) with the reference number ANR-15-IDEX-01. L. Kaminski is supported by the French Ministry of Research. S. Torrino has a grant from the Fondation de France. R. Haider and E. Jaune were supported by the foundation ARC and F.-R. Roustan by the CHU of Nice. I. Ben-Sahra is supported by the NIH R00-CA194192 and LAM Foundation grants. F. Bost, N. M. Mazure, and J.F. Tanti are CNRS investigators. Metabolomics services were performed by the Metabolomics Core Facility at Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Beth Israel Deaconess Medical Center Mass Spectrometry Facility of Harvard Medical School.

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'PGC1α inhibits polyamine synthesis to suppress prostate cancer aggressiveness'. Together they form a unique fingerprint.

Cite this